IP Library › Granted Patent US 7,838,000
Granted Patent B2
US 7,838,000 · App. 11/440,746 · Granted Nov 23, 2010

Inhibition of pathogenic agents including α6β1 integrin receptor or α6β4 integrin receptor at a surface

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,838,000
App. No.
11/440,746
Granted
Nov 23, 2010
Kind
B2
Abstract

Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6β1 integrin receptors and/or α6β4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 α3 chain that has been shown to bind α6β1 integrin receptors and α6β4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 α3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.

Claims (38)

1. A method comprising:

delivering a purified agent to a breast cancer cell, the purified agent including a polypeptide component consisting of the G3 subdomain of laminin-5 α3 chain, the G3 subdomain binding at least one of α6β1 and α6β4 integrin receptors;

binding the agent to the breast cancer cell, wherein the breast cancer cell includes at least one of α6β1 and α6β4 integrin receptors on a surface of the breast cancer cell; and

wherein upon binding the purified agent to the breast cancer cell, the proliferation of the breast cancer cell declines.

2. The method according to claim 1 , wherein the G3 subdomain of the laminin-5 α3 chain is SEQ ID NO:6.

3. The method according to claim 1 , wherein the purified agent consists of the G3 subdomain of the laminin-5 α3 chain.

4. The method according to claim 3 , wherein the agent is a recombinant polypeptide.

5. The method according to claim 1 , wherein the agent further comprises a second component bound to the first component.

6. The method according to claim 5 , wherein the second component is a polypeptide.

7. The method according to claim 6 , wherein the agent is a recombinant polypeptide.

8. The method according to claim 1 , further comprising providing the purified agent as a constituent of a composition.

9. The method according to claim 8 , the composition further comprising a biologically compatible constituent.

10. A method comprising:

delivering a purified agent to a breast cancer cell, the purified agent including a polypeptide component consisting of the G1-G3 subdomain of laminin-5 α3 chain, the polypeptide component binding at least one of α6β1 and α6β4 integrin receptors;

binding the agent to the breast cancer cell, wherein the breast cancer cell includes at least one of α6β1 and α6β4 integrin receptors on a surface of the breast cancer cell; and

wherein upon binding the purified agent to the breast cancer cell, the proliferation of the breast cancer cell declines.

11. The method according to claim 10 , wherein the G1-G3 subdomain of the laminin-5 α3 chain is SEQ ID NO:4.

12. The method according to claim 10 , wherein the agent consists of the G1-G3 subdomain of the laminin-5 α3 chain.

13. The method according to claim 12 , wherein the agent is a recombinant polypeptide.

14. The method according to claim 10 , wherein the agent further comprises a second component bound to the first component.

15. The method according to claim 14 , wherein the second component is a polypeptide.

16. The method according to claim 15 , wherein the agent is a recombinant polypeptide.

17. The method according to claim 10 , further comprising providing the purified agent as a constituent of a composition.

18. The method according to claim 17 , the composition further comprising a biologically compatible constituent.

19. A method comprising:

delivering a purified agent to a breast cancer cell, the purified agent including a polypeptide component consisting of the complete globular domain of laminin-5α3 chain, the polypeptide component binding at least one of α6β1 and α6β4 integrin receptors;

binding the agent to the breast cancer cell, wherein the breast cancer cell includes at least one of the α6β1 and α6β4 integrin receptors on a surface of the breast cancer cell; and

wherein upon binding the purified agent to the breast cancer cell, the proliferation of the breast cancer cell declines.

20. The method according to claim 19 , wherein the complete globular domain is SEQ ID NO:2.

21. The method according to claim 19 , wherein the agent consists of the complete globular domain of laminin-5α3 chain.

22. The method according to claim 21 , wherein the agent is a recombinant polypeptide.

23. The method according to claim 19 , wherein the agent further comprises a second component bound to the first component.

24. The method according to claim 23 , wherein the second component is a polypeptide.

25. The method according to claim 24 , wherein the agent is a recombinant polypeptide.

26. The method according to claim 19 , further comprising providing the purified agent as a constituent of a composition.

27. The method according to claim 26 , the composition further comprising a biologically compatible constituent.

28. The method according to claim 10 in which the purified agent comprises SEQ ID NO. 6.

29. The method according to claim 19 , in which the purified agent comprises SEQ ID NO. 6.